The use of Ebola Convalescent Plasma to treat Ebola Virus Disease in resource constrained settings: A perspective from the field.


van Griensven, J; De Weiggheleire, A; Delamou, A; Smith, PG; Edwards, T; Vandekerckhove, P; Bah, EI; Colebunders, R; Herve, I; Lazaygues, C; Haba, N; Lynen, L; (2016) The use of Ebola Convalescent Plasma to treat Ebola Virus Disease in resource constrained settings: A perspective from the field. Clinical infectious diseases , 62 (1). pp. 69-74. ISSN 1058-4838 DOI: 10.1093/cid/civ680

[img] Text - Published Version
License:

Download (171Kb)

Abstract

: The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, nonrandomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea, enrolled 102 patients by 7 July 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. Although no efficacy data are available yet, current field experience supports the safety, acceptability, and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from nontrial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.<br/>

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Tropical Epidemiology Group
PubMed ID: 26261205
Web of Science ID: 368621400011
URI: http://researchonline.lshtm.ac.uk/id/eprint/2287465

Statistics


Download activity - last 12 months
Downloads since deposit
136Downloads
275Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item